2026-06-24 イェール大学
An mRNA lipid nanoparticle (bottom left, yellow) producing anti-viral dimeric IgA antibodies (light yellow, center) that bind and neutralize incoming norovirus particles (teal, purple, and pink) in the gut. Illustration by Ella Marushchneko
＜関連情報＞
- https://news.yale.edu/2026/06/24/gut-punch-new-study-knocks-out-norovirus-where-it-strikes
- https://www.science.org/doi/10.1126/scitranslmed.aeb4878
IgAはマウスにおけるノロウイルス感染を予防するために必要かつ十分である IgA is necessary and sufficient to prevent norovirus infection in mice
Arya B. Ökten, Renata B. Filler, Justin L. Kung, Zhenhao Fang, […] , and Craig B. Wilen
Science Translational Medicine Published:24 Jun 2026
DOI:https://doi.org/10.1126/scitranslmed.aeb4878
Abstract
Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8+ T cells are dispensable. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure. In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.
